We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Detection and downregulation of type I IGF receptor expression by antibody-conjugated quantum dots in breast cancer cells.
- Authors
Zhang, Hua; Sachdev, Deepali; Wang, Chun; Hubel, Allison; Gaillard-Kelly, Martine; Yee, Douglas
- Abstract
The type I insulin-like growth factor (IGF) receptor (IGF1R) is a transmembrane tyrosine kinase involved in breast cancer proliferation, survival, and metastasis. Several monoclonal antibodies directed against the receptor are in clinical trials. In order to develop a methodology to detect and measure IGF1R levels in breast cancer cells, we covalently conjugated an IGF1R antibody, AVE-1642, with quantum dots (Qdots), which are nanocrystals that emit fluorescence upon excitation. AVE-1642 Qdots only bound to cells that express IGF1R, and measured IGF1R levels by fluorescence emission at 655 nm. After binding to the cell surface, AVE-1642 Qdots underwent receptor mediated endocytosis, localized to endosome, and later translocated into the nucleus. Treating MCF-7 cells with AVE-1642 Qdots, but not unconjugated Qdots alone, downregulated IGF1R levels and rendered cells refractory to IGF-I stimulation. Furthermore, cell proliferation was slightly inhibited by AVE-1642 Qdots, but not the unconjugated Qdots. Our data suggest that AVE-1642 Qdots can be used to detect IGF1R expression and measure changes in cell surface receptor levels. In addition, the inhibitory effect of AVE-1642 Qdots to cell proliferation implies that it may serve as a traceable therapeutic agent.
- Publication
Breast cancer research and treatment, 2009, Vol 114, Issue 2, p277
- ISSN
1573-7217
- Publication type
Journal Article
- DOI
10.1007/s10549-008-0014-5